ArticleFrontiers in bioinformatics2025
Food-derived linear vs. rationally designed cyclic peptides as potent TNF-alpha inhibitors: an integrative computational study.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peptide Aptamers: Innovative Design and Applications in Pathogen Detection.Chembiochem : a European journal of chemical biology · 2026Review
- Comparison of In Vitro Multiple Physiological Activities of Cys-Tyr-Gly-Ser-Arg (CYGSR) Linear and Cyclic Peptides and Analysis Based on Molecular Docking.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor necrosis factor-alpha (TNF-alpha) is a central mediator of chronic inflammation and a validated therapeutic target in atherosclerosis and related cardiovascular disorders. Peptide therapeutics offer high specificity and low toxicity; however, few natural sequences have been optimized for durable TNF-alpha inhibition. Methods: A dual in silico strategy was employed to identify potent inhibitors: (i) virtual screening of experimentally validated food-derived bioactive peptides and (ii) rational design of an N-C cyclized and disulfide-bridge peptide based on the TNF-alpha-TNFR1 interface. Molecular docking, 200-ns molecular dynamics simulations, and MM/PBSA free-energy analyses were performed. Results: The selected peptides exhibited strong and persistent interactions with key TNF-alpha residues, particularly Tyr119. The cyclic analogue demonstrated deeper free-energy minima, higher binding affinity, and more stable hydrogen-bond networks than the linear sequence. ADMET profiling revealed superior metabolic stability, reduced plasma clearance, and no predicted cardiotoxicity. Discussion: These results indicate that dietary peptides can serve as templates for TNF-alpha inhibition, and interface-guided cyclization rationally enhances stability, binding affinity, and drug-like properties. This study provides a mechanistic framework for developing food-derived peptides as next-generation TNF-alpha antagonists and supports United Nations SDGs 3 and 9 by promoting innovative, low-toxicity therapeutics for chronic inflammation and cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.